[go: up one dir, main page]

MX2010005225A - Derivados de fenilpirazol. - Google Patents

Derivados de fenilpirazol.

Info

Publication number
MX2010005225A
MX2010005225A MX2010005225A MX2010005225A MX2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A
Authority
MX
Mexico
Prior art keywords
alkyl
formula
halogen
heterocyclic ring
saturated
Prior art date
Application number
MX2010005225A
Other languages
English (en)
Inventor
Shigeyuki Chaki
Dai Nozawa
Tomoko Tamita
Toshio Nakamura
Makoto Tatsuzuki
Seiji Masuda
Hiroshi Ohta
Shuhei Kashiwa
Aya Fujino
Toshiharu Shimazaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2010005225A publication Critical patent/MX2010005225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención provee un agente profiláctico o terapéutico para demencia, enfermedad de Alzheimer, trastorno de hiperactividad por déficit de atención, esquizofrenia, epilepsia, convulsión central, trastornos de la alimentación, obesidad, diabetes, hiperlipidemia, trastornos del sueño, narcolepsia, síndrome de apnea durante el sueño, trastorno del ritmo circadiano, depresión, rinitis alérgica u otras enfermedades; un derivado de fenilpirazol representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo: (ver fórmula 1) (en donde R1 y R2, los cuales pueden ser iguales o diferentes, representan en cada caso alquilo(C1-C6) o cicloalquilo(C3-C8), o R1 y R2 están unidos uno a otro con su átomo adyacente de nitrógeno para formar un anillo heterocíclico saturado de 4 a 7 miembros (en donde dicho anillo heterocíclico saturado puede estar sustituido con halógeno o alquilo(C1-C6)), n representa un número entero de 0 a 2, T representa un átomo de hidrógeno, halógeno o alquilo(C1-C6), y R representa la fórmula (I): (ver fórmula I).
MX2010005225A 2007-11-13 2008-11-13 Derivados de fenilpirazol. MX2010005225A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2008153736 2008-06-12
PCT/JP2008/070712 WO2009063953A1 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体

Publications (1)

Publication Number Publication Date
MX2010005225A true MX2010005225A (es) 2010-05-27

Family

ID=40638800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005225A MX2010005225A (es) 2007-11-13 2008-11-13 Derivados de fenilpirazol.

Country Status (24)

Country Link
US (3) US7888354B2 (es)
EP (1) EP2221298B1 (es)
JP (2) JP4543344B2 (es)
KR (1) KR101571176B1 (es)
CN (1) CN101855211B (es)
AU (1) AU2008321823B2 (es)
BR (1) BRPI0820432B8 (es)
CA (1) CA2705502C (es)
CY (1) CY1114877T1 (es)
DK (1) DK2221298T3 (es)
ES (1) ES2436146T3 (es)
HR (1) HRP20131060T1 (es)
IL (2) IL205509A (es)
MX (1) MX2010005225A (es)
MY (1) MY173546A (es)
NZ (1) NZ585661A (es)
PH (1) PH12012501917A1 (es)
PL (1) PL2221298T3 (es)
PT (1) PT2221298E (es)
RS (1) RS53125B (es)
RU (1) RU2480456C2 (es)
SI (1) SI2221298T1 (es)
WO (1) WO2009063953A1 (es)
ZA (1) ZA201003111B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072724A1 (ja) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
WO2009063953A1 (ja) * 2007-11-13 2009-05-22 Taisho Pharmaceutical Co., Ltd. フェニルピラゾール誘導体
JP5740838B2 (ja) * 2009-05-12 2015-07-01 大正製薬株式会社 フェニルピラゾール誘導体
SG11201402963TA (en) * 2011-12-08 2014-09-26 Taisho Pharmaceutical Co Ltd Phenylpyrrole derivative
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2928474B1 (en) * 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
MX2015008830A (es) * 2013-01-17 2015-10-14 Hoffmann La Roche Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central.
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EP1311482B1 (en) 2000-08-08 2007-02-21 Ortho-McNeil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
US6316475B1 (en) 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
JP4612990B2 (ja) * 2001-03-16 2011-01-12 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての新規アミンおよびそれらの治療的適用
CN1812981A (zh) * 2003-06-27 2006-08-02 万有制药株式会社 杂芳氧基含氮饱和杂环衍生物
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
BRPI0514553A (pt) 2004-08-23 2008-06-17 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
ES2367515T3 (es) 2004-10-19 2011-11-04 F. Hoffmann-La Roche Ag Derivados de quinolina.
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
AU2005310467B2 (en) * 2004-12-01 2011-06-23 Msd K.K. Substituted pyridone derivative
EP1833796A1 (en) 2004-12-07 2007-09-19 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1866293A1 (en) 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
ES2510490T3 (es) 2005-04-01 2014-10-21 Eli Lilly And Company Agentes receptores de la histamina H3, preparación y usos terapéuticos
DE102005033448A1 (de) * 2005-07-18 2007-01-25 Josef Gail Druckgas-Zylinderläufermotor
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7897634B2 (en) * 2006-02-09 2011-03-01 Athersys, Inc. Pyrazoles for the treatment of obesity and other CNS disorders
WO2008072724A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
CN101711232A (zh) * 2007-04-12 2010-05-19 Dsm精细化学奥地利Nfg两合公司 邻-氯甲基苯基乙醛酸酯、(e)-2-(2-氯甲基苯基)-2-烷氧亚胺基乙酸酯的改进制备方法以及用于这些制备方法的新型中间体
WO2009063953A1 (ja) * 2007-11-13 2009-05-22 Taisho Pharmaceutical Co., Ltd. フェニルピラゾール誘導体

Also Published As

Publication number Publication date
NZ585661A (en) 2012-04-27
CN101855211A (zh) 2010-10-06
JP5375639B2 (ja) 2013-12-25
EP2221298B1 (en) 2013-11-06
IL205509A0 (en) 2010-12-30
US20100267687A1 (en) 2010-10-21
HRP20131060T1 (hr) 2013-12-20
JPWO2009063953A1 (ja) 2011-03-31
BRPI0820432B8 (pt) 2021-05-25
PH12012501917A1 (en) 2014-10-17
IL205509A (en) 2015-09-24
CA2705502A1 (en) 2009-05-22
PL2221298T3 (pl) 2014-05-30
CA2705502C (en) 2016-01-26
WO2009063953A1 (ja) 2009-05-22
US7888354B2 (en) 2011-02-15
ZA201003111B (en) 2011-08-31
AU2008321823B2 (en) 2013-03-07
DK2221298T3 (da) 2013-11-18
JP2010143943A (ja) 2010-07-01
JP4543344B2 (ja) 2010-09-15
AU2008321823A1 (en) 2009-05-22
US20110065668A1 (en) 2011-03-17
ES2436146T3 (es) 2013-12-27
IL236083A0 (en) 2015-01-29
CY1114877T1 (el) 2016-12-14
BRPI0820432B1 (pt) 2020-01-14
KR20100083795A (ko) 2010-07-22
US8183387B2 (en) 2012-05-22
BRPI0820432A2 (pt) 2015-05-26
PT2221298E (pt) 2013-12-03
SI2221298T1 (sl) 2013-12-31
EP2221298A4 (en) 2011-09-21
US8193176B2 (en) 2012-06-05
RU2480456C2 (ru) 2013-04-27
RS53125B (sr) 2014-06-30
IL236083A (en) 2016-12-29
EP2221298A1 (en) 2010-08-25
US20110065667A1 (en) 2011-03-17
RU2010123924A (ru) 2011-12-20
MY173546A (en) 2020-02-04
HK1145834A1 (en) 2011-05-06
CN101855211B (zh) 2013-06-12
KR101571176B1 (ko) 2015-11-23

Similar Documents

Publication Publication Date Title
MX2010005225A (es) Derivados de fenilpirazol.
BR112014003496A2 (pt) derivado heterocíclico e fármaco
AR067051A1 (es) Indazoles sustituidos, su preparacion y su utilizacion terapeutica
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
PA8534801A1 (es) Derivados de piperazina
AR036604A1 (es) Derivados de 4-pirimidona 3-sustituida
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
NO20076134L (no) Benzamidderivater og anvendelser derav
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
MX2011008336A (es) Derivados de dihidroquinolinona.
CR11095A (es) Compuestos amino-heterociclicos
AR082667A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
SE0104341D0 (sv) New use
UY27204A1 (es) Derivados de pieracina
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
MX2010001352A (es) Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares.
AR062295A1 (es) Compuesto de 1h-quinolin-4-ona, procedimientos para su preparacion y composicion farmaceutica
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
MX2016013412A (es) Derivados de morfolina-piridina.

Legal Events

Date Code Title Description
FG Grant or registration